## AMIFRU PLUS

## For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Abbreviated Prescribing information for **AMIFRU PLUS** [FDC of Torasemide 10mg and Amiloride 5mg] [Please refer the complete prescribing information available at <u>www.torrentpharma.com</u>]

**PHARMACOLOGICAL PROPERTIES**: Torasemide- It acts as a salidiuretic by inhibition of renal sodium and chloride reabsorption in the ascending limb of the loop of Henle. Amiloride- It interferes with transport of electrolytes in the nephron.

**INDICATION**: Treatment of oedema due to congestive heart failure; hepatic, pulmonary or renal oedema and hypertension oedema.

DOSAGE AND ADMINISTRATION: One tablet twice a day orally or as suggested by physician.

In individual cases, as much as 40mg torasemide/day has been administered. For Amiloride Initially 5mg twice daily, adjusted according to response and the dosage may be increased up to a maximum of 20mg daily.

**CONTRAINDICATION:** It is contraindicated in renal failure with anuria; hepatic coma and pre-coma; hypotension; pre-existing hypovolaemia; pregnancy and lactation; hypersensitivity, other potassium-sparing drugs and potassium supplements are contraindicated during this therapy. The safety of amifru plus for use in children under 18 years of age has not been established.

**WARNINGS & PRECAUTIONS**: Hypokalaemia, hyponatraemia, hypovolaemia and disorders of micturition must be corrected before treatment. On long-term treatment, regular monitoring of the electrolyte balance, glucose, uric acid, creatinine and lipids in the blood, is recommended. Careful monitoring of patients with a tendency to hyperuricaemia and gout is recommended. Carbohydrate metabolism in latent or manifest diabetes mellitus should be monitored, Particular caution is required in patients with difficulty with micturition including prostatic hypertrophy, given with caution to elderly patients, patients likely to develop acidosis, patients with diabetes mellitus and those with impaired hepatic or renal function.

**DRUG INTERACTIONS**: It may interact with cardiac glycosides, glucocorticoids and laxatives, aminoglycoside antibiotics, cisplatin preparations, cephalosporins, lithium, salicylates, non-steroidal antiinflammatory drugs, probenecid, colestyramine, alcohol, aldesleukin, antiarrhythmics, antidiabetic agents, antiepileptics such as carbamazepine, immunosuppressants, nitrates, alprostadil and carbenoxolone.

**ADVERSE REACTIONS**: Thrombocytopenia, leukopenia, anaemia, allergic skin reactions, metabolic alkalosis, fluid and electrolyte imbalance, headache, dizziness, cerebral ischaemia, parenthesia, confusional state, visual impairment, tinnitus, deafness, acute myocardial infarction, myocardial ischaemia, angina pertoris, gastrointestinal disorder, hepatic enzyme increased, muscle spasms, urinary retention, bladder dilatation, fatigue, asthenia, decreased libido, somnolence, encephalopathy, paraesthesia, palpitations, postural hypotension and impotence.

## MARKETED BY:



TORRENT PHARMACEUTICALS LTD. Torrent House, Off Ashram Road, Ahmedabad-380 009, INDIA

IN/AMIFRU PLUS 5,10mg/MAY-22/02/ABPI

(Additional information is available on request)